Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$65.64 +6.5%	$61.05	$43.70 ▼ $86.53	$2.09B	-1.48	49,171 shs	26,717 shs
CGON CG Oncology	$26.23 +3.8%	$23.13	$14.80 ▼ $40.47	$2.00B	1.08	829,202 shs	634,925 shs
NAMS NewAmsterdam Pharma	$17.63 +1.8%	$18.19	$14.06 ▼ $27.29	$1.94B	0.01	642,027 shs	359,498 shs
RGNX REGENXBIO	$8.97 +5.0%	$7.87	$5.04 ▼ $15.36	$449.94M	1.11	892,200 shs	1.09 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-0.03%	-8.44%	+2.38%	+5.75%	+35.26%
CGON CG Oncology	-0.94%	-3.59%	-9.62%	+2.60%	-22.05%
NAMS NewAmsterdam Pharma	+1.76%	-6.48%	-2.92%	-17.22%	-10.82%
RGNX REGENXBIO	-5.84%	-11.41%	-6.46%	+29.39%	-42.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.1757 of 5 stars	3.5	3.0	0.0	1.9	0.8	0.6
CGON CG Oncology	2.4509 of 5 stars	4.5	1.0	0.0	3.1	0.8	0.0
NAMS NewAmsterdam Pharma	2.5007 of 5 stars	3.5	1.0	0.0	2.1	5.0	0.0
RGNX REGENXBIO	4.2271 of 5 stars	3.4	1.0	4.6	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	47.27% Upside
CGON CG Oncology	3.00	Buy	$58.22	121.97% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	143.90% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	252.56% Upside

Current Analyst Ratings Breakdown

Latest RGNX, BLTE, CGON, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
4/28/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00 ➝ $75.00
4/28/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/16/2025	CGON CG Oncology	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$23.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
CGON CG Oncology	$662K	3,020.21	N/A	N/A	($1.94) per share	-13.52
NAMS NewAmsterdam Pharma	$47.14M	41.07	N/A	N/A	$3.50 per share	5.04
RGNX REGENXBIO	$156.72M	2.87	N/A	N/A	$7.09 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.36	N/A	N/A	N/A	N/A	-31.94%	-30.73%	8/8/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)

Latest RGNX, BLTE, CGON, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
CGON CG Oncology	N/A	35.32	35.32
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CGON CG Oncology	26.56%
NAMS NewAmsterdam Pharma	89.89%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CGON CG Oncology	7.40%
NAMS NewAmsterdam Pharma	20.84%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable

RGNX, BLTE, CGON, and NAMS Headlines

Recent News About These Companies

Millennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 26 at 3:53 AM | marketbeat.com

BNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 25, 2025 | marketbeat.com

Q2 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs

May 24, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLC

May 23, 2025 | marketbeat.com

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress

May 22, 2025 | investing.com

REGENXBIO FY2025 EPS Forecast Reduced by Chardan Capital

May 21, 2025 | marketbeat.com

REGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 20, 2025 | finanznachrichten.de

REGENXBIO announces royalty monetization agreement for up to $250M

May 20, 2025 | msn.com

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025 | prnewswire.com

FY2025 EPS Estimate for REGENXBIO Decreased by Analyst

May 19, 2025 | americanbankingnews.com

Point72 Asia Singapore Pte. Ltd. Makes New $447,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 18, 2025 | marketbeat.com

Hudson Bay Capital Management LP Has $2.38 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

May 16, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

May 15, 2025 | insidertrades.com

US FDA accepts and grants priority review status to Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II

May 15, 2025 | pharmabiz.com

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts

May 15, 2025 | finance.yahoo.com

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Integral Health Asset Management LLC

May 14, 2025 | marketbeat.com

FDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory Application

May 13, 2025 | precisionmedicineonline.com

Regenxbio stock rises on FDA’s priority review for MPS II therapy

May 13, 2025 | investing.com

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13, 2025 | prnewswire.com

Cubist Systematic Strategies LLC Makes New $2.79 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, BLTE, CGON, and NAMS Company Descriptions

Belite Bio NASDAQ:BLTE

$65.64 +4.03 (+6.54%)

Closing price 04:00 PM Eastern

Extended Trading

$65.64 0.00 (-0.01%)

As of 07:08 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

CG Oncology NASDAQ:CGON

$26.23 +0.95 (+3.76%)

Closing price 04:00 PM Eastern

Extended Trading

$24.52 -1.72 (-6.54%)

As of 05:41 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

NewAmsterdam Pharma NASDAQ:NAMS

$17.63 +0.32 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$17.64 +0.02 (+0.09%)

As of 04:04 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

REGENXBIO NASDAQ:RGNX

$8.97 +0.43 (+5.04%)

Closing price 04:00 PM Eastern

Extended Trading

$8.91 -0.06 (-0.61%)

As of 08:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time